In this regard it is noteworthy that much of the recent efforts at developing disease-modifying therapies for AD have focused on Aβ and Tau and include immunotherapy, drugs to reduce Aβ production or increase clearance, and drugs to inhibit Tau phosphorylation or polymerization, but these have yet to show success in the clinic [57,60,61]. Here, MAPT is linked to Alzheimer disease.